Hypertrophic Cardiomyopathy (HCM) Clinical Trials

Find Hypertrophic Cardiomyopathy (HCM) Clinical Trials Near You

A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• Diagnosis of nHCM

• On a stable regimen of guideline-directed medical therapy for nHCM

• NYHA functional class II or III

• NT-proBNP \>300 pg/mL

• Body weight of 50 to 100 kg, inclusive, and BMI ≤40 kg/m2, inclusive

• Adequate renal function

• Not pregnant, and willing to use acceptable birth control methods

• Able and willing to comply with study procedures

Locations
United States
Massachusetts
Lahey Clinic
RECRUITING
Boston
Missouri
Saint Luke's Health System
RECRUITING
Kansas City
Ohio
The Lindner Research Center at The Christ Hospital
RECRUITING
Cincinnati
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2027-03
Participants
Target number of participants: 10
Treatments
Experimental: Open-label evaluation of multiple doses of HTX-001 in participants with symptomatic nHCM
Open label evaluation of multiple doses of HTX-001, across 2-3 dose levels, in participants with symptomatic nHCM who are receiving standard of care therapy
Sponsors
Leads: Haya Therapeutics, Inc.

This content was sourced from clinicaltrials.gov